2023/04/20

Dong-A ST, led by CEO Min-Young Kim, unveiled the results of preclinical trials for their immuno-oncology candidate, DA-4505, at the American Association for Cancer Research (AACR) 2023 conference held in Orlando, Florida, from the 14th to the 19th of September.

During this conference, Dong-A ST presented posters highlighting the "Anti-Tumor Effects of DA-4505 as a Novel Aryl Hydrocarbon Receptor (AhR) Antagonist in the Tumor Microenvironment" and "Enhanced Efficacy of Anti-Cancer Surgery and Chemotherapy through the Action of the Novel AhR Antagonist DA-4505."

DA-4505 is an AhR antagonist that regulates the immune system, suppressing immune responses and preventing attacks on tumor cells. In preclinical trials, DA-4505 demonstrated its ability to restore suppressed immune responses in the tumor microenvironment by inhibiting AhR. Furthermore, it activated stimulatory immune cells, such as dendritic and T cells, while reducing the immune-inhibitory functions of cancer cells.

Compared to AhR antagonists under development by global pharmaceutical companies, DA-4505 exhibited improved tumor suppression effects. Combining DA-4505 with a global pharmaceutical company's PD-1 immune checkpoint inhibitor enhanced tumor suppression.

Dr. Jae-Hong Park, the Head of R&D at Dong-A ST, stated, "Global pharmaceutical companies are actively developing new mechanisms for anticancer agents, particularly AhR antagonists. The preclinical results of DA-4505 have shown its AhR inhibition capabilities, immune activation, and reduction in immune suppression effects. We plan to apply for Phase 1 clinical trials (IND) for DA-4505 in the second quarter of this year."

Dong-A ST's promising results with DA-4505 have generated significant interest in its potential as a novel candidate in cancer immunotherapy. 

Source: http://www.whosaeng.com/143571